Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

NCT05051943 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.

NCT NCT05051943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05051943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Lead sponsor
Fresenius Kabi
Phase
Observational
Overall status
Completed
Start date
September 29, 2020
Completion date
January 20, 2023
Enrollment
754 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, crohn disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis